[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:atr-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"ATR Gene",5,3,[8,16,22,28,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[12],"Phase 2","RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.292506Z",{"nct_id":29,"title":30,"phases":31,"status":32,"updated_at":33,"content_modified":34},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":36,"title":37,"phases":38,"status":39,"updated_at":40,"content_modified":41},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]